Tom 3, Nr 4 (2010)
SPRAWOZDANIA, KOMUNIKATY
Opublikowany online: 2010-12-29
Wyświetlenia strony
367
Wyświetlenia/pobrania artykułu
854
Nowe strategie lecznicze Przegląd sesji XXIX Kongresu Światowego Stowarzyszenia Chorych na Hemofilię, Buenos Aires (Argentyna), 10–14 lipca 2010 roku
Journal of Transfusion Medicine 2010;3(4):169-171.
Streszczenie
Brak
Referencje
- Cao Ou, Hoffman BE, Moghimi B, et al. Impact of the underlying mutation and the route of vector administration on immune responses to factor IX in gene therapy for hemophilia B. Mol Ther. 2009; 17(10): 1733–1742.
- Collins PW, Blanchette VS, Fischer K, et al. rAHF-PFM Study Group. Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A. J Thromb Haemost. 2009; 7(3): 413–420.
- Batorova A, High KA, Gringeri A. Special lectures in haemophilia management. Haemophilia. 2010; 16 Suppl 5: 22–28.
- Dimichele D. Immune tolerance therapy for factor VIII inhibitors: moving from empiricism to an evidence-based approach. J Thromb Haemost. 2007; 5 Suppl 1: 143–150.
- Hay CR. M., Goldberg I., Foulkes M., DiMichele D.M.; on behalf of the International Immune Tolerance Study Group. International prospective randomized immune tolerance (ITI) study: interim analysis of therapeutic efficacy and safety. Haemophilia. 2010; 16(405): abstract P5.
